




Docket No.: 250512US55DIV

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313



ATTORNEYS AT LAW

RE: Application Serial No.: 10/815,707

Applicants: Alan K. SMITH, et al.

Filing Date: April 2, 2004

For: HUMAN LINEAGE COMMITTED CELL  
COMPOSITION WITH ENHANCED  
PROLIFERATIVE POTENTIAL, BIOLOGICAL  
EFFECTOR FUNCTION, OR BOTH; METHODS FOR  
OBTAINING SAME; AND THEIR USES

Group Art Unit: 1644

Examiner: BELYAVSKI, M.A.

SIR:

Attached hereto for filing are the following papers:

**RESPONSE TO RESTRICTION REQUIREMENT**

Our check in the amount of \_\_\_\_\_ is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Jean-Paul Lavalleye

Registration No. 31,451


Customer Number

**22850**

(703) 413-3000 (phone)  
(703) 413-2220 (fax)

Daniel J. Pereira, Ph.D.  
Registration No. 45,518

DOCKET NO: 250512US55DIV



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :  
ALAN K. SMITH, ET AL. : EXAMINER: BELYAVSKI, M.A.  
SERIAL NO: 10/815,707 :  
FILED: APRIL 2, 2004 : GROUP ART UNIT: 1644  
FOR: HUMAN LINEAGE COMMITTED :  
CELL COMPOSITION WITH ENHANCED  
PROLIFERATIVE POTENTIAL,  
BIOLOGICAL EFFECTOR FUNCTION,  
OR BOTH; METHODS FOR OBTAINING  
SAME; AND THEIR USES

RESPONSE TO RESTRICTION REQUIREMENT

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Restriction Requirement dated March 24, 2005, Applicants elect,  
with traverse, Group I.

**Remarks/Arguments** begin on page 2 of this paper.